Advertisement

What do radiation oncologists require for future advancements in lung SBRT?

Published:December 01, 2016DOI:https://doi.org/10.1016/j.ejmp.2016.11.114

      Highlights

      • SBRT is the non-surgical standard option for patients with early stage lung cancer.
      • Risk-adapted SBRT is highly effective and low toxic for both peripheral and central tumors.
      • SBRT use is increasing for lung metastases, in combination with systemic agents.
      • Standardization of planning and delivery processes is essential in further developing SBRT.
      • Further technical advances are essential for safely expanding SBRT indications.

      Abstract

      Stereotactic Body Radiotherapy (SBRT) is a well established therapeutic option for patients affected with peripheral early stage non-small cell lung cancer (NSCLC), given the positive clinical evidence accumulated so far on its efficacy and safety. SBRT is regarded as the best choice for inoperable patients, and could also be offered as an alternative to surgery to selected operable patients. More recently, its use for lung metastases progressively increased, and SBRT is now regarded as a low toxic and highly effective local therapy for lung oligometastases from different primary tumors, especially colorectal cancer. Improved planning and delivery techniques have facilitated over the years its use on large and/or centrally located primary tumors, and multiple nodules. Given the successful applications and the current wide dissemination of this technique, clinicians are now faced with an increasingly complex and multi-variable decision process. Some clinically relevant factors are still uncertain, and strategies are needed to reduce the risk of both local and distant failures. Secondly, aspects related to target delineation, dose prescription, image guidance and treatment planning still need to be fully addressed; this may hamper, at least for now, the standardization of SBRT procedures through different Institutions making any kind of direct outcomes comparison difficult. We here aim to provide a perspective on the current role of lung SBRT and its critical aspects, highlighting the potential future developments.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Physica Medica: European Journal of Medical Physics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Blomgren H.
        • Lax I.
        • Näslund I.
        • Svanström R.
        Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients.
        Acta Oncol. 1995; 34: 861-870
        • Uematsu M.
        • Shioda A.
        • Tahara K.
        • et al.
        Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience.
        Cancer. 1998; 82: 1062-1070
        • Wulf J.
        • Hӓdinger U.
        • Oppitz U.
        • Olshausen B.
        • Flentje M.
        Stereotactic radiotherapy of extracranial targets: CT-simulation and accuracy of treatment in the stereotactic body frame.
        Radiother Oncol. 2000; 57: 225-236
        • Timmerman R.
        • Papiez L.
        • McGarry R.
        • et al.
        Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer.
        Chest. 2003; 124: 1946-1955
      1. Senan S, Guckenberger M, Ricardi U. Stage I NSCLC and oligometastatic disease. IASLC Textbook Multidisciplinary approach to Thoracic Oncology; 2014, 1st ed.

      2. NCCN Non-Small Cancer Guidelines Version 7.2015. Available at <https://www.nccn.org/>.

        • McGarry R.
        • Papiez L.
        • Williams M.
        • Whitford T.
        • Timmerman R.
        Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study.
        Int J Radiat Oncol Biol Phys. 2005; 63: 1010-1015
        • Hoyer M.
        • Roed H.
        • Hansen A.T.
        • et al.
        Prospective study on stereotactic radiotherapy of limited-stage non-small-cell lung cancer.
        Int J Radiat Oncol Biol Phys. 2006; 66: S128-S135
        • Baumann P.
        • Nyman J.
        • Hoyer M.
        • et al.
        Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy.
        J Clin Oncol. 2009; 27: 3290-3296
        • Timmerman R.
        • Paulus R.
        • Galvin J.
        • et al.
        Stereotactic body radiation therapy for inoperable early stage lung cancer.
        JAMA. 2010; 303: 1070-1076
        • Ricardi U.
        • Filippi A.R.
        • Guarneri A.
        • et al.
        Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial.
        Lung cancer. 2010; 68: 72-77
        • Bral S.
        • Gevaert T.
        • Linthout N.
        • et al.
        Prospective, risk- adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a phase II trial.
        Int J Radiat Oncol Biol Phys. 2011; 80: 1343-1349
        • Guckenberger M.
        • Allgäuer M.
        • Appold S.
        • et al.
        Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis.
        J Thorac Oncol. 2013; 8: 1050-1058
        • Ricardi U.
        • Frezza G.
        • Filippi A.R.
        • et al.
        Stereotactic ablative radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study.
        Lung Cancer. 2014; 84: 248-253
        • Senthi S.
        • Lagerwaard F.J.
        • Haasbeek C.J.A.
        • Slotman B.J.
        • Senan S.
        Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
        Lancet Oncol. 2012; 13: 802-809
        • Haasbeek C.J.A.
        • Lagerwaard F.L.
        • Antonisse M.E.
        • Slotman B.J.
        • Senan S.
        Stage I non small cell lung cancer in patients aged ⩾75 years.
        Cancer. 2010; 15: 406-414
        • Palma D.
        • Visser O.
        • Lagerwaard F.J.
        • Belderbos J.
        • Slotman B.
        • Senan S.
        Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I Non-Small Cell Lung Cancer: a population-based time-trend analysis.
        J Clin Oncol. 2010; 28: 5153-5159
        • Vansteenkiste J.
        • Crinò L.
        • Dooms C.
        • et al.
        2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.
        . 2014; 25: 1462-1474
        • Nyman J.
        • Hallqvist A.
        • Lund J.A.
        • et al.
        SPACE - a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC.
        . 2014; 111: 232(S)
        • Chi A.
        • Liao Z.
        • Nguyen N.P.
        • Xu J.
        • Stea B.
        • Komaki R.
        Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications.
        Radiother Oncol. 2010; 94: 1-11
        • Shultz D.B.
        • Trakul N.
        • Abelson J.A.
        • et al.
        Imaging features associated with disease progression after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer.
        Clin Lung Cancer. 2014; 15: 294-301
        • De Ruysscher D.
        18F-deoxyglucose uptake in stage I non-small-cell lung cancer: time to move to randomized trials.
        J Thorac Oncol. 2014; 9: 5-6
        • Louie A.V.
        • Haasbeek C.J.
        • Mokhles S.
        • et al.
        Predicting overall survival after stereotactic ablative radiation therapy in early-stage lung cancer: development and external validation of the Amsterdam prognostic model.
        Int J Radiat Oncol Biol Phys. 2015; 93: 82-90
        • Mokhles S.
        • Verstegen N.
        • Maat A.
        • et al.
        Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis.
        Lung Cancer. 2015; 87: 283-289
        • Stanic S.
        • Paulus R.
        • Timmerman R.D.
        • et al.
        No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236.
        Int J Radiat Oncol Biol Phys. 2014; 88: 1092-1099
        • Ferrero C.
        • Badellino S.
        • Filippi A.R.
        • et al.
        Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study.
        Lung Cancer. 2015; 89: 350-356
        • Lagerwaard F.J.
        • Aaronson N.K.
        • Gundy C.M.
        • Haasbeck C.J.
        • Slotman B.J.
        • Senan S.
        Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer.
        J Thorac Oncol. 2012; 7: 1148-1154
        • Sibley G.S.
        • Jamieson T.A.
        • Marks L.B.
        • Anscher M.S.
        • Prosnitz L.R.
        Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience.
        Int J Radiat Oncol Biol Phys. 1998; 40: 149-154
        • Joiner M.
        • Van der Kogel A.
        Basic clinical radiobiology.
        4th ed. Hodder Arnold, London2009
        • Onishi H.
        • Araki T.
        • Shirato H.
        • et al.
        Stereotactic hypofractionated high-dose irradiation for stage I non- small cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese Multiinstitutional Study.
        Cancer. 2004; 101: 1623-1631
        • Wulf J.
        • Baier K.
        • Mueller G.
        • Flentje M.P.
        Dose-response in stereotactic irradiation of lung tumors.
        Radiother Oncol. 2005; 77: 83-87
        • Kestin L.
        • Grills I.
        • Guckenberger M.
        • et al.
        Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance.
        Radiother Oncol. 2014; 110: 499-504
        • Koshy M.
        • Malik R.
        • Weichselbaum R.
        • Sher D.
        Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for Stage I non–small-cell lung cancer.
        Int J Radiat Oncol Biol Phys. 2015; 91: 344-350
        • Videtic G.
        • Hu C.
        • Singh A.
        • et al.
        NRG oncology RTOG 0915 (NCCTG N0927): a randomized Phase II study comparing 2 stereotactic body radiation therapy (SBRT) schedules for medically inoperable patients with Stage I peripheral non-small cell lung cancer.
        Int J Radiat Oncol Biol Phys. 2015; 93: 757-764
        • Shuryak I.
        • Carlson D.J.
        • Brown J.M.
        • Brenner D.J.
        High-dose and fractionation effect in stereotactic radiation therapy: analysis of tumor control data from 2965 patients.
        Radiother Oncol. 2015; 115: 327-334
        • Ohri N.
        • Werner-Wasik M.
        • Grills I.
        • et al.
        Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the Elekta Collaborative lung research group.
        Int J Radiat Oncol Biol Phys. 2012; 84: e379-e384
        • Van Baardwijk A.
        • Tomè W.
        • Van Elmpt W.
        • et al.
        S high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review.
        Radiother Oncol. 2012; 105: 145-149
        • Chang J.Y.
        • Bezjak A.
        • Mornex F.
        Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned.
        J Thorac Oncol. 2015; 10: 577-585
        • Timmerman R.
        • McGarry R.
        • Yiannoutsos C.
        • et al.
        Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.
        J Clin Oncol. 2006; 24: 4833-4839
        • Senthi S.
        • Haasbeek C.J.A.
        • Slotman B.J.
        • Senan S.
        Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review.
        Radiother Oncol. 2013; 106: 276-282
        • Nestle U.
        • Faivre-Finn C.
        • Deruysscher D.
        • et al.
        Stereotactic body radiotherapy (SBRT) in central non-small cell lung cancer (NSCLC): solid evidence or ‘no-go’?.
        Radiother Oncol. 2013; 109: 178-179
        • Chang J.Y.
        • Li Q.
        • Xu Q.
        • et al.
        Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “no fly zone”.
        Int J Radiation Oncol Biol Phys. 2014; 88: 1120-1128
        • Chaudhuria A.A.
        • Tanga C.
        • Binkleya M.S.
        • et al.
        Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.
        Lung Cancer. 2015; 89: 50-56
      3. www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails=0813.

        • Ricardi U.
        • Badellino S.
        • Filippi A.R.
        Clinical applications of stereotactic radiotherapy for oligometastatic cancer patients: a disease-oriented approach.
        J Rad Res. 2016; (Mar 8. pii: rrw006. [Epub ahead of print])
        • Niibe I.
        • Hayakawa K.
        Oligometastases and oligo-recurrence: the new era of cancer therapy.
        Jpn J Clin Oncol. 2010; 40: 107-111
        • Shultz D.B.
        • Filippi A.R.
        • Thariat J.
        • Mornex F.
        • Loo Jr, B.W.
        • Ricardi U.
        Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer.
        J Thorac Oncol. 2014; 9: 1426-1433
        • Palma D.A.
        • Salama J.K.
        • Lo S.S.
        • et al.
        The oligometastatic state: separate truth from wishful thinking.
        Nat Rev Clin Oncol. 2014; 11: 549-557
        • Filippi A.R.
        • Badellino S.
        • Ceccarelli M.
        • et al.
        Stereotactic ablative radiation therapy as first local therapy for lung oligometastases from colorectal cancer: a single-institution cohort study.
        Int J Radiat Oncol Biol Phys. 2015; 91: 524-529
        • Filippi A.R.
        • Guerrera F.
        • Badellino S.
        • et al.
        Exploratory analysis on overall survival after either surgery or stereotactic radiotherapy for lung oligometastases from colorectal cancer.
        Clin Oncol (R Coll Radiol). 2016; 28: 505-512
        • Ugurel S.
        • Rohmel S.
        • Ascierto P.A.
        • et al.
        Survival of patients with advanced metastatic melanoma: the impact of novel therapies.
        Eur J Canc. 2016; 53: 125-134
      4. Herzberg B, Campo MJ, Gainor JF. Immune checkpoint inhibitors in non-small cell lung cancer. Oncologist. 2016 Aug 17. pii: theoncologist.2016-0189. [Epub ahead of print].

        • Demaria S.
        • Pilones K.A.
        • Vanpouille-Box C.
        • Golden E.B.
        • Formenti S.C.
        The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation.
        Radiat Res. 2014; 182: 170-181
        • Formenti S.C.
        • Demaria S.
        Combining RT and cancer immunotherapy: a paradigm shift.
        J Natl Canc Inst. 2013; 105: 256-265
        • Filippi A.R.
        • Fava P.
        • Badellino S.
        • Astrua C.
        • Ricardi U.
        • Quaglino P.
        Radiotherapy and immune checkpoint inhibitors for advanced melanoma.
        Radiother Oncol. 2016; 120: 1-12
        • Dammeijer F.
        • Lievense L.A.
        • Marijn Veerman G.D.
        • et al.
        The efficacy of tumor vaccines and cellular immunotherapies in non-small cell lung cancer: a systematic review and meta-analysis.
        J Clin Oncol. 2016; 34: 3204-3212
      5. Sharma RA, Plummer R, Stock JK, et al. Clinical development of new drug-radiotherapy combinations. Nat Rev Clin Oncol 2016 adv online publication.

        • Baker S.
        • Dahele M.
        • Lagerwaard F.J.
        • Senan S.
        A critical review of recent developments in radiotherapy for non-small cell lung cancer.
        Rad Onc. 2016; 11: 115
        • Allison R.
        • Dicker A.
        Radiation oncology: physics advances that minimize morbidity.
        Future Oncology. 2014; 10: 2329-2344
        • Harada K.
        • Katoh N.
        • Suzuki R.
        • et al.
        Evaluation of the motion of lung tumors during stereotactic body radiation therapy (SBRT) with four-dimensional computed tomography (4DCT) using real-time tumor-tracking radiotherapy system (RTRT).
        Physica Med. 2016; 32: 305-311
        • Stavrev P.
        • Ruggieri R.
        • Stavreva N.
        • Naccarato S.
        • Alongi F.
        Applying radiobiological plan ranking methodology to VMAT prostate SBRT.
        Physica Med. 2016; 32: 636-641